CYTH Overview
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading chart...
The current price of CYTH is 0 USD — it has increased 0
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Company’s Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimer’s disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimer’s disease (NCT03624842).
Wall Street analysts forecast CYTH stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTH is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Cyclo Therapeutics Inc revenue for the last quarter amounts to 233.77K USD, decreased -52.82
Cyclo Therapeutics Inc. EPS for the last quarter amounts to -0.31 USD, increased 6.90
Cyclo Therapeutics Inc (CYTH) has 8 emplpoyees as of April 03 2026.
Today CYTH has the market capitalization of 34.34M USD.
